Pharmacyclics, Inc. - Product Pipeline Review - 2012

Summary

“Pharmacyclics, Inc. - Product Pipeline Review - 2012” provides data on the Pharmacyclics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Pharmacyclics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Pharmacyclics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Pharmacyclics, Inc. - Brief Pharmacyclics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Pharmacyclics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Pharmacyclics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Pharmacyclics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Pharmacyclics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Pharmacyclics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Pharmacyclics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Pharmacyclics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Pharmacyclics, Inc. and identify potential opportunities in those areas.

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Pharmacyclics, Inc. Snapshot 6
Pharmacyclics, Inc. Overview 6
Key Information 6
Key Facts 6
Pharmacyclics, Inc. – Research and Development Overview 7
Key Therapeutic Areas 7
Pharmacyclics, Inc. – Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products –  Monotherapy 11
Pipeline Products – Combination Treatment Modalities 12
Pharmacyclics, Inc. – Pipeline Products Glance 13
Pharmacyclics, Inc. – Late Stage Pipeline 13
Phase III Products/Combination Treatment Modalities 13
Pharmacyclics, Inc. Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Pharmacyclics, Inc. – Early Stage Pipeline Products 16
Pre-Clinical Products/Combination Treatment Modalities 16
Pharmacyclics, Inc. – Drug Profiles 17
abexinostat 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
BTK Inhibitors For Autoimmune Diseases 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
ibrutinib 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Motexafin Gadolinium + Temozolomide 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
PCI-27483 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
PCI-32765 + Bendamustine + Rituximab 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
PCI-32765 + Fludarabine + Cyclophosphamide + Rituximab 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
PCI-32765 + Ofatumumab 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
PCI-32765 + Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone 31
Product Description 31
Mechanism of Action 31
R&D Progress 32
PCI-34051 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
PCI-45261 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Pharmacyclics, Inc. – Pipeline Products by Route of Administration 35
Pharmacyclics, Inc. – Pipeline Products By Mechanism of Action 36
Pharmacyclics, Inc. –  Recent Pipeline Updates 38
Pharmacyclics, Inc. - Dormant Projects 43
Pharmacyclics, Inc. - Discontinued Pipeline Products 44
Discontinued Pipeline Product Profiles 44
PCI-45292 44
Pharmacyclics, Inc. – Company Statement 45
Pharmacyclics, Inc. – Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Pharmacyclics, Inc., Recent Developments 48
Pharmacyclics, Inc.- Press Release 48
Oct 15, 2012: Pharmacyclics Triggers Another Significant Milestone Payment For Phase III Chronic Lymphocytic Leukemia Combination Trial 48
Aug 20, 2012: Pharmacyclics Triggers Significant Milestone Payment For Mantle Cell Lymphoma Clinical Trial 49
Aug 01, 2012: Pharmacyclics To Receive $50m Milestone Payment From Janssen Biotech 49
Jun 16, 2012: Pharmacyclics Announces Updated Results For Ibrutinib At European Hematology Association Annual Congress 50
Jun 16, 2012: Pharmacyclics Announces Updated Results For Ibrutinib Combination Study At European Hematology Association Annual Congress 51
Jun 04, 2012: Pharmacyclics Presents Updated Results From Phase Ib/II CLL/SLL Combination Study Of Ibrutinib With Atumumab At ASCO Annual Meeting 51
Jun 04, 2012: Pharmacyclics Presents Updated Results From Phase Ib/II CLL/SLL Trial Of Ibrutinib At ASCO 2012 Annual Meeting 52
Jun 04, 2012: Pharmacyclics Presents Updated Safety And Efficacy Data From Phase Ib/II CLL/SLL Combination Trial Of PCI-32765 With Bendamustine And Rituximab At ASCO Annual Meeting 53
May 22, 2012: Pharmacyclics Announces Oral Presentations Of Ibrutinib At 17th Congress Of European Hematology Association 54
May 17, 2012: Pharmacyclics Announces Oral Presentations And Clinical Update Of Ibrutinib At ASCO 2012 Annual Meeting 54
Dec 06, 2009: Pharmacyclics, Inc. Reports Interim Safety And Clinical Data From A Phase I/II Clinical Trial Of Its Oral HDAC Inhibitor PCI-24781 In Lymphoma At The American Society Of Hematology Annual Meeting 55
Apr 16, 2009: Pharmacyclics Updates Positive Clinical Responses In Its PCI-24781 Clinical Program Targeting HDAC 56
Apr 13, 2009: Pharmacyclics Initiates Phase 1 Clinical Trial Of Novel Oral Btk Inhibitor For Refractory B-cell Non-Hodgkin's Lymphoma 57
Financial Deals Landscape 58
Pharmacyclics, Inc., Deals Summary 58
Pharmacyclics, Inc., Pharmaceuticals & Healthcare, Deal Details 59
Asset Transactions 59
Pharmacyclics Acquires Cancer Drug Candidates And Intellectual Property From Celera Genomics 59
Partnerships 61
Pharmacyclics Enters Into Co-Development Agreement With National Cancer Institute For PCI-32765 61
Pharmacyclics Enters Into Collaboration With Servier 63
Licensing Agreements 65
Janssen Biotech Enters Into Licensing Agreement With Pharmacyclics For PCI-32765 65
Equity Offering 67
Pharmacyclics Files Registration Statement For A Public Offering For $150 Million 67
Pharmacyclics Completes Private Placement Of Common Stock For $57 Million 68
Pharmacyclics Completes Registered Direct Offering Of Common Stock For $52 Million 70
Pharmacyclics Completes Rights Offering Of $29 Million 72
Pharmacyclics Completes Private Placement Of $1 Million 74
Pharmacyclics Completes Underwritten Public Offering Of $22.74 Million 76
Appendix 78
Methodology 78
Coverage 78
Secondary Research 78
Primary Research 78
Expert Panel Validation 78
Contact Us 79
Disclaimer 79

List of Tables
Pharmacyclics, Inc., Key Information 6
Pharmacyclics, Inc., Key Facts 6
Pharmacyclics, Inc. – Pipeline by Indication, 2012 9
Pharmacyclics, Inc. – Pipeline by Stage of Development, 2012 10
Pharmacyclics, Inc. – Monotherapy Products in Pipeline, 2012 11
Pharmacyclics, Inc. – Combination Treatment Modalities in Pipeline, 2012 12
Pharmacyclics, Inc. – Phase III, 2012 13
Pharmacyclics, Inc. – Phase II, 2012 14
Pharmacyclics, Inc. – Phase I, 2012 15
Pharmacyclics, Inc. – Pre-Clinical, 2012 16
Pharmacyclics, Inc. – Pipeline By Route of Administration, 2012 35
Pharmacyclics, Inc. – Pipeline Products By Mechanism of Action, 2012 37
Pharmacyclics, Inc. – Recent Pipeline Updates, 2012 38
Pharmacyclics, Inc. - Dormant Developmental Projects,2012 43
Pharmacyclics, Inc. - Discontinued Pipeline Products, 2012 44
Pharmacyclics, Inc., Subsidiaries 47
Pharmacyclics, Inc., Deals Summary 58
Pharmacyclics Acquires Cancer Drug Candidates And Intellectual Property From Celera Genomics 59
Pharmacyclics Enters Into Co-Development Agreement With National Cancer Institute For PCI-32765 61
Pharmacyclics Enters Into Collaboration With Servier 63
Janssen Biotech Enters Into Licensing Agreement With Pharmacyclics For PCI-32765 65
Pharmacyclics Files Registration Statement For A Public Offering For $150 Million 67
Pharmacyclics Completes Private Placement Of Common Stock For $57 Million 68
Pharmacyclics Completes Registered Direct Offering Of Common Stock For $52 Million 70
Pharmacyclics Completes Rights Offering Of $29 Million 72
Pharmacyclics Completes Private Placement Of $1 Million 74
Pharmacyclics Completes Underwritten Public Offering Of $22.74 Million 76

List of Figures
Pharmacyclics, Inc.  – Pipeline by Indication, 2012 8
Pharmacyclics, Inc.  – Pipeline by Stage of Development, 2012 10
Pharmacyclics, Inc. – Monotherapy Products in Pipeline, 2012 11
Pharmacyclics, Inc. – Combination Treatment Modalities in Pipeline, 2012 12
Pharmacyclics, Inc.  – Pipeline By Route of Administration, 2012 35
Pharmacyclics, Inc.  - Pipeline Products By Mechanism of Action, 2012 36